Quarterly report pursuant to Section 13 or 15(d)

Stockholders' equity (Tables)

v3.23.1
Stockholders' equity (Tables)
9 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Schedule of warrants or rights
The activity related to warrants during the nine months ended March 31, 2023, is summarized as follows:
 
            Weighted-  
            average  
            Exercise  
     Common      Price  
     Stock from      (per  
     Warrants      share)  
Outstanding at July 1, 2022
     107,095      $ 10.50  
Pre-funded
warrants issued September 15, 2022
     12,171,628      $ 0.0001  
Series 2 Warrants issued September 15, 2022
     29,809,471      $ 0.66  
    
 
 
    
 
 
 
Outstanding at September 30, 2022
     42,088,194      $ 0.49  
Pre-funded
warrants exercised
     2,171,628      $ 0.0001  
    
 
 
    
 
 
 
Outstanding at March 31, 2023
     39,916,566      $ 0.52  
    
 
 
    
 
 
 
Exercisable at March 31, 2023
     39,916,566      $ 0.52  
    
 
 
    
 
 
 
Schedule of equity awards
The activity related to equity awards, which are comprised of stock options during the nine months ended March 31, 2023 is summarized as follows:
 
                   Weighted-         
            Weighted-      average         
            average      Remaining      Aggregate  
     Stock      Exercise      Contractual      Intrinsic  
     Options      Price      Term      Value  
Outstanding at June 30, 2022
     738,064      $ 6.95        7.18 years      $ —    
    
 
 
    
 
 
                   
Expired
     5,665      $ 45.92                    
    
 
 
    
 
 
                   
Granted
     36,000      $ 0.17        9.93 years           
Outstanding at March 31, 2023
     768,399      $ 6.35        6.64 years      $ 1,501  
    
 
 
    
 
 
                   
Exercisable at March 31, 2023
     456,688      $ 8.58        6.46 years      $ —    
    
 
 
    
 
 
                   
Schedule of equity-based compensation expense
The classification of share-based compensation expense is
summarized
as follows:
 
     Three Months Ended      Nine Months Ended  
     March 31, 2023  
(US$’000)    2023      2022      2023      2022  
Research and development
   $ 27      $ 63      $ 87      $ 224  
General and administrative
     44        129        238        478  
Total share-based compensation expense
   $ 71      $ 192      $ 325      $ 702